Relistor (methylnaltrexone) Use Expanded to Noncancer Patients

The FDA approved Movantik (nalogel) last month and the anticonstipation medication already has competition. First approved in 2008, injectable Relistor (methylnaltrexone) treated constipation in patients taking opioids for chronic pain related to cancer. Now, it is estimated that over 10 million people will benefit from the new indication.

Results from one study were encouraging: a third of treated patients had a bowel movement with 4 hours, and half moved their bowels before even receiving a second dose. The fact that Relistor (methylnaltrexone) has to be injected may keep some patients away. It is likely that an oral version will be introduced in the future.

To read the article, click here.

To read about the FDA approval of Movantik (naloxegol), click here.


Related Content